Acepodia Stock

Acepodia is a therapeutics company that employs flexible therapeutic design to treat cancer.

Sign up today and learn more about Acepodia Stock

Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.

About Acepodia Stock

Acepodia is a clinical-stage biotechnology business that is using its proprietary Antibody-Cell Conjugation (ACC) platform technology to produce first-in-class cell treatments to solve gaps in cancer care. Acepodia employs this live-cell compatible chemistry to attach tumor-targeting antibodies directly to a variety of immune cell receptors, enhancing the lock between immune and cancer cells and generating highly specific, potent cell therapies without the need for genetic engineering. Acepodia is committed to immunotherapeutic strategies against oncology – expanding our research, clinical development, and manufacturing capabilities. Acepodia currently has a broad pipeline portfolio, each targeting a different type of cancer.

Funding History

March 2021$47.0M
December 2021$109M
June 2023$100M

Management

Board of Directors

Samuel Chen

Chief Scientific Advisor

Carolyn Bertozzi

Chairman

Patrick Y. Yang

CEO, President & Co-Founder

Sonny Hsiao

Co-Founder

Patrick Y. Yang

Press

Join 630,000+ Investors and Shareholders

On our trusted digital marketplace for private companies

EquityZen Recognized As:

Logo